Neratinib
Specifications
698387-09-6CAS Number
811-237-1EC Number
(E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamideIUPAC Name
C30H29ClN6O3Chemical Formula
557 g/molMolecular Weight
Neratinib; 698387-09-6; HKI-272; HKI 272; JJH94R3PWB; (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide; PB-272; CDP-820; PB 272; HKI272; CHEBI:61397; DTXSID70220132; (2e)-n-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-; N-(4-(3-Chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide; (2E)-N-(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; (2E)-N-[4-({3-chloro-4-[(pyridin-2-yl)methoxy]phenyl}amino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide; 2-Butenamide, N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-, (2E)-; neratinibum; (2E)-N-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; RefChem:56993; DTXCID70142623; L10XE45; Neratinib (HKI-272); Nerlynx; (2E)-N-[4-[[3-Chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide; MFCD09752958; (E)-N-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; CHEMBL180022; WAY-179272; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide; C30H29ClN6O3; (E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; Neratinib [USAN]; Neratinib [USAN:INN]; UNII-JJH94R3PWB; 698387-09-6 (free base); Neratinib (Standard); NERATINIB [INN]; NERATINIB [MI]; Neratinib (USAN/INN); NERATINIB [MART.]; NERATINIB [WHO-DD]; Neratinib (HKI-272)?; SCHEMBL571762; Neratinib - Bio-X trade mark; GTPL5686; orb1224203; orb1305687; SCHEMBL29376313; SCHEMBL29394766; EX-A062; GLXC-90246; HMS5087D17; BDBM50161957; EBC-27314; HY-32721R; NSC757439; NSC800803; s2150; WAY-179272-B; AKOS005146340; AKOS025149637; CCG-270036; DB11828; FN65101; NSC-757439; NSC-800803; SDCCGSBI-0654392.P001; NCGC00241101-01; NCGC00241101-03; NCGC00241101-07; NCGC00241101-08; NCGC00241101-09; (E)-N-[4-[3-chloro-4-(2-pyridylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolyl]-4-(dimethylamino)but-2-enamide; AC-25073; AS-16279; BN164645; BP-44032; HY-32721; N1062; N1868; NS00069565; D08950; EN300-7386009; F794019; Q6995920; BRD-K85606544-001-01-8; BRD-K85606544-001-09-1; (2E)-N-(4-{3-Chloro-4-[(pyridin-2-yl)methoxy]anilino}-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; (E)-4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide; 4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide; N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)butanamideSynonyms
